Full Press Release Details
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
MIRM Positive Sentiment
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Key Takeaway: Mirum Pharmaceuticals has announced an upcoming investor call to discuss the topline results from the Phase 3 EXPAND study of LIVMARLI® (maralixibat). This study targets ultra-rare cholestatic liver diseases, highlighting the company's commitment to addressing significant medical needs. The call aims to provide insights into the findings and implications for future treatments.
Market Sentiment Analysis
POSITIVE FACTORS
- Mirum Pharmaceuticals is sharing topline results from a significant study.
- The Phase 3 EXPAND study focuses on LIVMARLI® for rare liver diseases.
- The investor call indicates transparency and engagement with stakeholders.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~36 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX
Frequently Asked Questions
What is the purpose of the investor call?
The investor call aims to share topline results from the Phase 3 EXPAND study.
What is LIVMARLI® used for?
LIVMARLI® (maralixibat) is being studied for ultra-rare cholestatic liver diseases.
What phase is the EXPAND study?
The EXPAND study is a Phase 3 clinical trial.
Where is Mirum Pharmaceuticals located?
Mirum Pharmaceuticals is based in Foster City, California.